Holtkamp and colleagues observed dose-dependent inhibition of MPNST cell proliferation mediated by erlotinib, an EGFR-targeted tyrosine kinase inhibitor [19]. This evidence concerns the gene EGFR and malignant peripheral nerve sheath tumor.